alexa Michael Mullan | OMICS International
ISSN: 0974-276X

Journal of Proteomics & Bioinformatics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
  • Glycobiology, Lipids & Proteomics
    August 27-28, 2018 Toronto, Canada
  • Computational Biology and Bioinformatics
    Sep 05-06 2018 Tokyo, Japan
  • Advancements in Bioinformatics and Drug Discovery
    November 26-27, 2018 Dublin, Ireland
View More»

Michael Mullan

Roskamp Institute


Dr. Mike Mullan is a recognized authority on Alzheimer's disease and related disorders. Dr Mullan is a co-discoverer of the first ever genetic causes of Alzheimer's disease. Consequently, he was a co-inventor on the original patents covering three mutations in the amyloid precursor protein (APP) gene. He also co-authored the nature and nature genetics paper describing these three genetic errors,He was senior author on two of those manuscripts.

Dr. Mullan's Alzheimer work resulted in identifying the most widely mutation known as the Swedish Mutation that is present in familial form. Transgenic Animal models for Alzheimer Disease frequently use the Swedish Mutation to reproduce features of the disease.

Dr. Michael Mullan was trained as a physician in England receiving his medical degree from London University. He subsequently gained a PhD in molecular genetics, also from London University. He is an inventor on the patents covering the first ever genetic mutations linked to familial Alzheimer's disease. He has co-authored over 200 papers on Alzheimer's disease and related disorders—on many of which he served as senior author. He has held positions a Professorial Chair and positions as professor of Psychiatry, Neurology, and Pathology. He cofounded the Roskamp Institute, a not-for-profit, stand-alone biomedical research Institute and served in the past as the Director and CEO. The institute is funded by multiple agencies, including the NIH and the Department of Defense. The Roskamp Institute is dedicated to the discovery and development of new treatments for neuropsychiatric disorders including Alzheimer’s disease, traumatic brain injury, Gulf War illness and a variety of related conditions. Dr Mullan serves as the CEO of Archer Pharmaceuticals, a for-profit spin-off of the Roskamp Institute. Archer Pharmaceuticals developed a drug which is currently in phase 3 clinical trials in nine countries in Europe.

Dr. Michael Mullan along with a team of neuroscientists at the Roskamp Institute invented the Brain Reserve Index, a numerical index that indicates risk of developing Alzheimer's Disease.

Dr. Mike Mullan has published over 200 research papers mostly on the causes and potential treatments of Alzheimer’s disease and other central nervous system diseases.

Dr. Michael Mullan is currently the CEO and Chairman of the Board for Rockcreek Pharmaceuticals.

Research Interest

Alzheimer's disease, molecular genetics, Psychiatry, Neurology and Pathology


Proteomic Analysis of Human Neuronal Cells Treated with the Gulf War Agent Pyridostigmine Bromide

Laila Abdullah, Jon Reed, Gogce Kayihan, Venkat Mathura, Benoit Mouzon, Michael Mullan, Fiona Crawford

Research Article: J Proteomics Bioinform Vol.2.10 439-444(2009)

DOI: 10.4172/jpb.1000103

Global Speakers in the subject

Global Experts in the subject

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7